Merck &amp, Co has announced that phase 2 clinical trials of its investigational once-weekly DPP-4 inhibitor, in development for the treatment of type 2 diabetes, have been effective. The drug ...

Merck already has the world’s biggest selling oral treatment for type 2 diabetes, its DPP-4-based drugs Januvia and Janumet, but it is playing catch-up in the SGLT2 market. The monotherapy and ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

diabetes and related diseases. Dean Li, president of Merck Research Laboratories, said in the statement that the drug had “potential to provide additional cardiometabolic benefits beyond weight ...

Merck is also seeing weakness in the diabetes franchise and the generic erosion of some drugs. Merck’s shares have lost 23.5% in the past year compared with a decrease of 4.3% for the industry.

Presently, Merck only markets and sells one other oncology drug exclusively ... or 9% of revenues, diabetes segment that earned $2.3bn, or 4% of revenues, virology segment, $1.8bn, 2% of revenues ...

Valued at a market cap of $226.1 billion, Merck & Co., Inc. (MRK) is a healthcare company that boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda approved for ...

Rising competitive pressure on the diabetes franchise and persistent ... better analyze how to play Merck stock. Merck boasts more than six blockbuster drugs in its portfolio, with blockbuster ...